Want to see TSE:BCT full AI Analyst Report?
Top Page
BriaCell Therapeutics
(TSX:BCT)
Select Model
Select Model
Rating:50Neutral
Price Target:
C$5.00
▼(-53.01% Downside)
Action:Reiterated
Date:07/07/26
The score is primarily constrained by weak financial performance driven by ongoing losses and significant cash burn despite a net-cash, no-debt balance sheet. Technicals provide a modest offset with improving short-term price strength but a weaker longer-term trend. Valuation remains unfavorable due to negative earnings and no dividend yield data.
Positive Factors
Net-cash, no-debt balance sheet
A net-cash, zero-debt posture and rising shareholders' equity materially reduce leverage risk for a pre-revenue biotech. This structural strength gives the company greater financial flexibility to fund clinical programs, pursue partnerships, or raise capital on less dilutive terms over the medium term.
Negative Factors
Pre-revenue with sustained large losses
Being pre-revenue with persistent, sizable operating losses means the company cannot self-fund operations and must rely on external financing. Over the medium term this elevates dilution and execution risk, making clinical milestones and capital access determinative for survival and growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Net-cash, no-debt balance sheet
A net-cash, zero-debt posture and rising shareholders' equity materially reduce leverage risk for a pre-revenue biotech. This structural strength gives the company greater financial flexibility to fund clinical programs, pursue partnerships, or raise capital on less dilutive terms over the medium term.
Read all positive factors
BriaCell Therapeutics (BCT) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$45.85M
Dividend YieldN/A
Average Volume (3M)3.11K
Price to Earnings (P/E)―
Beta (1Y)1.60
Revenue GrowthN/A
EPS Growth85.31%
CountryCA
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-12.20
Shares Outstanding8,699,787
10 Day Avg. Volume3,860
30 Day Avg. Volume3,110
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.24
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BriaCell Therapeutics Business Overview & Revenue Model
Company Description
BriaCell Therapeutics Corp. is a biotechnology company focused on immuno-oncology, dedicated to developing innovative immune-based therapies for cancer treatment. Its primary therapeutic candidate, Bria-IMT, is a whole-cell cancer vaccine currentl...
How the Company Makes Money
As a clinical-stage biotech company, BriaCell does not have publicly established, recurring product sales as a primary revenue source; instead, its operations are typically funded through external financing and other non-commercial sources common ...
BriaCell Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
56
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -26.59K | -107.93K | 0.00 | 0.00 | 0.00 | -15.55K |
| EBITDA | -31.48M | -27.43M | -4.85M | -23.26M | -26.82M | -7.10M |
| Net Income | -30.65M | -26.63M | -4.79M | -20.30M | -26.84M | -13.82M |
Balance Sheet | ||||||
| Total Assets | 27.07M | 21.72M | 5.87M | 27.16M | 42.58M | 58.04M |
| Cash, Cash Equivalents and Short-Term Investments | 22.80M | 17.93M | 862.09K | 21.25M | 41.04M | 57.27M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.99K |
| Total Liabilities | 3.66M | 4.33M | 8.56M | 30.94M | 32.25M | 30.37M |
| Stockholders Equity | 24.06M | 17.94M | -2.38M | -3.78M | 10.33M | 27.67M |
Cash Flow | ||||||
| Free Cash Flow | -31.01M | -28.51M | -24.58M | -23.74M | -12.48M | -7.75M |
| Operating Cash Flow | -30.88M | -28.51M | -24.13M | -23.74M | -12.48M | -7.75M |
| Investing Cash Flow | -16.57M | -7.74M | -681.80K | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 41.33M | 46.00M | 4.42M | 3.95M | -3.74M | 65.00M |
BriaCell Therapeutics Technical Analysis
Positive
10.64
Price Trends
4.78
Positive
5.21
Positive
8.86
Negative
Market Momentum
0.08
Negative
67.00
Neutral
79.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BCT, the sentiment is Positive. The current price of 10.64 is above the 20-day moving average (MA) of 4.32, above the 50-day MA of 4.78, and above the 200-day MA of 8.86, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 67.00 is Neutral, neither overbought nor oversold. The STOCH value of 79.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BCT.
BriaCell Therapeutics Risk Analysis
BriaCell Therapeutics disclosed 50 risk factors in its most recent earnings report. BriaCell Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BriaCell Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | C$42.63M | -7.32 | -8.01% | ― | -34.81% | -453.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$45.85M | -0.30 | -147.92% | ― | ― | 85.31% | |
45 Neutral | C$15.55M | -3.99 | 75.85% | ― | 33.00% | 40.74% | |
42 Neutral | C$34.38M | -2.65 | 7.84% | ― | ― | 58.17% |
* Healthcare Sector Average
TSE:BCT
BriaCell Therapeutics
5.17
-22.83
-81.54%
TSE:DOSE
Rapid Dose Therapeutics Corp
0.12
-0.09
-42.86%
TSE:MBX
Microbix Biosystms
0.30
<0.01
1.69%
TSE:RVX
Resverlogix
0.10
0.06
122.22%
TSE:GSD
Devonian Health Group
9.00
0.00
0.00%
TSE:TTI
Thiogenesis Therapeutics Corp
0.56
-0.22
-28.21%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.